



INVESTORPresentation

NOVEMBER 2021

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Heranba Industries Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

CONTENTS

O1 COMPANY OVERVIEW
SLIDE 04

02 MANAGEMENT TEAM SLIDE 11

O3 QUARTERLY PERFORMANCE

04 FINANCIAL PERFORMANCE
SLIDE 18

05 STRATEGY FOR GROWTH SLIDE 23





HERANBA AT GLANCE

SLIDE 05

OUR JOURNEY

SLIDE 06

VALUE CHAIN

SLIDE 07

INTERMEDIARIES

SLIDE 08

TECHNICALS

SLIDE 09

FORMULATIONS

SLIDE 10

Overview

HERANBA at a Glance





Manufacturing Facilities



60+ **Countries Presence**



650+

Employees (as of FY21)



77.70%

Revenue from Institutional customers** (as of H1 FY22)



9400+

Dealers across India



35%

Revenue from Exports as % of sales (as of H1 FY22)



Approx. 25%

Revenue from Top 10 customers (as of H1 FY22)



32.38%

(as of H1 FY22)

Our Journey



1996

CMAC

 Started manufacturing the Intermediate CMAC





TECHNICALS

 Forward integrated into the manufacturing of Technicals, primarily made from the raw material CMAC and other Intermediates



2006

BRANDED FORMULATIONS

 Forward Integrated into Branded Formulations through its own distribution network





2005

FORMULATIONS

 Forward integrated into the manufacturing of Formulations developed from Company's synthetic pyrethroids product portfolio of cypermethrin, alphacypermethrin, deltamethrin, permitherin, lambda cyhalothrin



2020

EXPORTS

 Exported Technicals and Formulations to more than 60 countries in the international markets



2021

INITIAL PUBLIC OFFERING

Listed on BSE & NSE





2014

ISO CERTIFICATE

 Receipt of ISO 9001:2015 certification in respect of production & dispatch of agro Formulations and packing & dispatch of agro based herbicides



2019

TURNOVER

 Achieved Turnover of ₹1000 Crores



Value Chain


Value Chain



HIL over the years, has scaled up the manufacturing of Intermediates, Technicals and Formulations which form part of the entire value chain of the agrochemicals industry

Manufacturing Process

- HIL manufactures a wide range of products, and each product has its own unique manufacturing process
- The Company specializes in the manufacturing processes that mainly include chemical reactions of:



The process of manufacturing can be classified broadly into three stages



Intermediaries

Intermediates

Cypermethric Acid Chloride (CMAC) High CIS CMA

High CIS CMAC

High Trans CMA

High Trans CMAC

Bromobenzenes

Metaphenoxy Benzaldehyde (MPBD)

End-use


Intermediates manufactured are for Company's own captive consumption for manufacturing various Technicals and Formulations



Technicals

Insecticides


- Cypermethrin
- Deltamethrin
- Alpha Cypermethrin
- Acephate
- Lambda Cyhalothrin
- Permethrin
- Profenophos
- Temephos
- Theta Cypermethrin
- Thiamethoxam
- Imidacloprid




Formulations

Insecticides

- Jayam
- Progress Plus
- Param
- Cypraplus
- Dyken
- Mantra
- Astron
- Signor
- Prompt
- Cypra
- Heraban
- Alpha Shakti
- Henoxa







Experienced Promoters with Domain Knowledge

Promoters having a cumulative experience of more than six decades



Mr. Sadashiv K. Shetty

CHAIRMAN AND EXECUTIVE DIRECTOR

- Holds a bachelor's (physics and chemistry) and master's (chemistry) degree in science from University of Mysore
- Has experience of more than three decades in agrochemicals industry
- Has been on Board since September, 1994 and is responsible for the overall supervision, direction and management of the Company
- He has been instrumental in new products development and addition of capacities
- Has previously worked with Sudarshan Chemical Limited, Gharda Chemical Limited, Hoechst Pharmaceuticals and Nirlon Limited



Mr. Raghuram K. Shetty

MANAGING DIRECTOR

- Holds a bachelor's degree in economics from University of Mysore
- Subsequently, pursued government commercial diploma from the Department of Education, Bureau of Government Examinations, Maharashtra and completed diploma in export and import management from the India International Trade Centre, Mumbai
- Has experience of more than three decades in agrochemicals industry
- Has been on Board since September, 1994 and is fully involved in day-to-day affairs of the Company
- He has been instrumental in developing export business for the Company

Management Expertise

Mr. Rajkumar Bafna

CHIEF FINANCIAL OFFICER

- Holds a bachelor's degree in commerce from University of Bombay and is an associate member of the Institute of Chartered Accountants of India
- He has 18+ years of industry experience in the field of accounts, corporate finance and management information systems
- Oversees overall finance and accounting, risk management and audit compliance in the Company

Mr. Rajesh Ohri

VICE PRESIDENT - PROCUREMENT & BUSINESS DEVELOPMENT

- Holds a bachelor's degree in engineering (production) from Shivaji University, Kolhapur
- He has several years of experience in field of supply chain management and procurement of raw materials
- Looks after procurement department along with business development function of the Company

Mr. Mopidevi V. Rao

HEAD OF R&D DIVISION

- Holds a bachelor's and master's degree (organic chemistry) degree in science from Andhra University
- He has also done Ph.D. in chemistry from GITAM University
- He has experience of more than two decades in the field of agro formulations of insecticides, fungicides and herbicides
- Looks after development of new products & has control over the R&D activities in the Company
- Has previously been associated with Insecticides (India) Limited, Nagarjuna Agrichem Limited and Solaris Chemtech Limited



Q1FY22 Financial Highlights

Revenue from Operations at ₹3534.35 million in Q2FY22 as compared to ₹3491.79 million in Q2FY21 – growth of 1.22% Y-o-Y and growth of 0.58% Q-o-Q.

EBITDA (incl. other income) at ₹663.50 million in Q2FY22 as compared to ₹565.78 million in Q2FY21 – growth of 17.27% Y-o-Y and de-growth of 3.97% Q-o-Q.


EBITDA (incl. other income)
Margins were at 18.77% in
Q2FY22 as compared to 16.20%
in Q2FY21 – growth of approx.
257bps Y-o-Y and de-growth of
89bps Q-o-Q.

Profit After Tax at ₹456.15 million in Q2FY22 as compared to ₹377.28 million in Q2FY21 – growth of 20.90% Y-o-Y and degrowth of 3.74% Q-o-Q.




Quarterly Performance


Net Revenue from Operations




EBITDA(incl. Other Rev) and **EBITDA Margin**



PAT and PAT Margin



Business Mix



Profit & Loss Summary (Quarterly)

(₹ IN MILLION)

(CIT INITELION			
Q2FY21	Q1FY22	Q2FY22	
2401.70	2 514 06	252425	
	·	3534.35 51.7	
3499.32	3,556.79	3586.05	
2986.59	2913.69	2971.97	
512.73	643.10	614.08	
135.45	169.23	157.93	
377.28	473.87	456.15	
9.66	11.84	11.4	
9.66	11.84	11.4	
565.78	690.91	663.50	
16.20%	19.66%	18.77%	
	3491.79 7.53 3499.32 2986.59 512.73 135.45 377.28 9.66 9.66	3491.79 3,514.06 7.53 42.73 3499.32 3,556.79 2986.59 2913.69 512.73 643.10 135.45 169.23 377.28 473.87 9.66 11.84 9.66 11.84 565.78 690.91	




KEY Ratios


Net Revenue from Operations

(₹ IN MILLION) FY19 FY20 FY21 H1 FY22


EBITDA(incl. Other Rev) and EBITDA Margin



PAT and PAT Margin





Net Debt/(Cash) and Equity



Business Mix

Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market





Profit & Loss Summary

(₹	IN	MII	LLI	ON)
---	---	----	-----	-----	-----

PARTICULARS	FY19	FY20	FY21	H1 FY22
Revenue from Operations	10,044.44	9,513.74	12,186.47	7,048.41
Other Income	73.94	165.32	70.30	94.43
Total Revenue	10,118.38	9,679.06	12,256.77	7,142.84
Total Expenses	8,897.18	8,390.64	10,173.92	5,885.66
Profit Before Tax	1,221.2	1,288.42	2,082.85	1,257.18
Total Tax Expense	467.18	311.85	540.59	327.17
Profit After Tax	754.02	976.57	1,542.26	930.01
EPS Basic (₹)	19.31	25.00	39.41	23.24
EPS Diluted (₹)	19.31	25.00	39.41	23.24
EBITDA (incl. Other Income)	1,388.07	1,458.82	2,283.69	1,354.41
EBITDA (incl. Other Income) Margin	13.82%	15.33%	18.74%	19.22%

Balance Sheet (1/2)

				(₹ IN MILLION)
PARTICULARS	FY19	FY20	FY21	H1 FY22
Non-Current Assets				
Property, plant and equipment	511.39	954.41	1,334.35	1,388.88
Capital work-in-progress	159.70	377.72	96.95	209.76
Financial Assets:				
(i) Investments	0.24	37.31	100.98	20.86
(ii) Other Financial Assets	71	84.27	241.71	74.12
Current tax assets (Net)	1.48		10.20	33.00
Other non-current assets	344.58	80.66	97.01	231.28
Total Non-Current Assets (I)	1,088.39	1,534.37	1,881.20	1,957.90
Current Assets				
Inventories	1,138.94	1,455.18	1,659.86	2,468.08
Financial Assets:				
(i) Trade Receivables	2,532.72	2,584.67	3,417.62	4,394.76
(ii) Cash and cash equivalents	209.65	31.94	847.80	585.83
(iii) Loans	0	8.95		
(iv) Other financial assets	15.4	17.17	19.97	20.79
Other current assets	619.33	615.35	606.68	463.33
Total Current Assets (II)	4,516.04	4,713.26	6,551.93	7,932.79
Total Assets (I + II)	5,604.43	6,247.63	8,433.13	9,890.69

Balance Sheet (2/2)

				(₹ IN MILLION)
PARTICULARS	FY19	FY20	FY21	H1 FY22
Equity and liabilities				
Equity				
Equity share capital	390.56	390.56	400.13	400.13
Other equity	1891.2	2817.93	4881.21	5808.32
Total Equity	2281.76	3208.49	5281.34	6208.45
Liabilities				
Non-Current Liabilities				
Financial Liabilities				
(i) Borrowings				
(ii) Other Financial Liabilities	57.27	61.46	66.41	69.6
Provisions	4.22	6.49	22.43	31.7
Other Non-current liabilities		2.28	11.71	10.71
Deferred Tax balances (net)	41.27	16.09		
Total Non-Current Liabilities (I)	102.76	86.32	100.55	112.01
Current Liabilities				
Financial Liabilities				
(i) Borrowings	498.74	430.79	502.79	456.64
(ii) Trade payables	2352.07	2124.68	1955.82	2428.85
(iii) Other Financial Liabilities	121.89	139.30	283.27	265.01
Current tax Balances (net)	101.68	37.46	88.37	113.28
Other current liabilities	96.46	163.19	159.73	230.33
Provisions	49.07	57.40	61.25	76.12
Total Current Liabilities (II)	3219.91	2952.82	3051.24	3570.23
Total Liabilities (I + II)	3322.67	3039.14	3151.79	3682.24
TOTAL EQUITY AND LIABILITIES	5604.43	6247.63	8433.13	9890.69

Cashflow Statement

(₹ IN MILLION)

PARTICULARS	FY19	FY20	FY21	H1 FY22
Cash Flow from Operations	877.02	542.11	603.98	-81.77
Cash Flow from Investing Activities	-373.79	-520.39	-407.13	-305.24
Cash Flow from financing Activities	-411.35	-199.43	619.01	-72.08
Net increase/ (decrease) in cash and cash equivalents	91.88	-177.71	815.86	-459.09
Cash and cash equivalents at beginning of the year	117.77	209.65	31.94	847.80
Cash and cash equivalents at end of the year	209.65	31.94	847.80	388.71




COMPETITIVE STRENGTHS


SLIDE 26

BUSINESS STRATEGY

SLIDE 27

Competitive Strengths





THANK YOU

CONTACT US:

Investor Relations

Kanav Khanna <u>kkhanna@christensenir.com</u> Diwakar Pingle <u>dpingle@christensenir.com</u>

CORPORATE OFFICE

Heranba Industries Ltd.

101/102, Kanchanganga, Factory Lane, Borivali (W), Mumbai – 400 092, India

Tel: 91-22-2898 7912/14,

91-22-2898 2133/44,

91-22-2898 4439,

91-22-5070 5050

Email: compliance@heranba.com

